SG11201900405XA - Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia - Google Patents
Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemiaInfo
- Publication number
- SG11201900405XA SG11201900405XA SG11201900405XA SG11201900405XA SG11201900405XA SG 11201900405X A SG11201900405X A SG 11201900405XA SG 11201900405X A SG11201900405X A SG 11201900405XA SG 11201900405X A SG11201900405X A SG 11201900405XA SG 11201900405X A SG11201900405X A SG 11201900405XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- alcalde
- ste
- california
- gout
- Prior art date
Links
- 201000005569 Gout Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000001431 Hyperuricemia Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000002269 Cytochrome P-450 CYP2C9 Human genes 0.000 abstract 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 230000007056 liver toxicity Effects 0.000 abstract 1
- 230000037353 metabolic pathway Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI HIM vu 1101 0 0111111111111111111111H1111111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/017368 Al 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: C07D 307/80 (2006.01) A61K 31/343 (2006.01) (21) International Application Number: PCT/US2017/041763 (22) International Filing Date: 12 July 2017 (12.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/363,473 18 July 2016 (18.07.2016) US (71) Applicant: ARTHROSI THERAPEUTICS, LLC [US/US]; 23052 Alcalde Drive, Suite A, Laguna Hills, Cal- ifornia 92653 (US). (72) Inventors: YAN, Shunqi; 23052 Alcalde Dr., Ste. A, La- guna Hills, California 92653 (US). YEH, Li-TaM; 23052 Alcalde Drive, Ste A, Laguna Hills, California 92653 (US). ORR, Robert; 23052 Alcalde Dr., Ste. A, Laguna Hills, California 92653 (US). (74) Agent: KIM, Rosie et al.; FISH IP LAW, LLP, 2603 Main Street, Ste. 1000, Irvine, California 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States indicated, (84) (unless otherwise for every kind ARIPO GH, of regional protection available): (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European AT, BE, BG, DE, DK, (AL, CH, CY, CZ, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (BF, KM, ML, MR, NE, SN, TD, TG). ,— I Published: ..! — with international search report (Art. 21(3)) GC M IN 1-1 0 —.... 00 1-1 (54) Title: COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTON ASSOCIATED 0 N WITH GOUT OR HYPERURICEMIA C (57) : The inventive subject matter provides compounds, compositions and methods for lowering serum acid (sUA) for the treatment of gout, and having reduced liver toxicity, associated with CYP2C9 metabolic pathway.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363473P | 2016-07-18 | 2016-07-18 | |
| PCT/US2017/041763 WO2018017368A1 (en) | 2016-07-18 | 2017-07-12 | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900405XA true SG11201900405XA (en) | 2019-02-27 |
Family
ID=60992707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900405XA SG11201900405XA (en) | 2016-07-18 | 2017-07-12 | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US10239854B2 (en) |
| EP (2) | EP3957629B1 (en) |
| JP (3) | JP2019524747A (en) |
| KR (1) | KR102610573B1 (en) |
| CN (3) | CN109790135B (en) |
| AU (1) | AU2017298142B2 (en) |
| CA (1) | CA3030821A1 (en) |
| DK (1) | DK3484862T3 (en) |
| EA (1) | EA201990333A1 (en) |
| ES (2) | ES2897968T3 (en) |
| IL (1) | IL264268B (en) |
| PL (1) | PL3484862T3 (en) |
| PT (1) | PT3484862T (en) |
| SG (1) | SG11201900405XA (en) |
| WO (1) | WO2018017368A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2988050A1 (en) | 2015-06-09 | 2016-12-15 | Lymphact - Lymphocyte Activation Technologies, S.A. | Methods for the production of tcr gamma delta+ t cells |
| AU2017298142B2 (en) | 2016-07-18 | 2021-11-11 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| KR20210100677A (en) * | 2018-12-06 | 2021-08-17 | 아쓰로시 테라퓨틱스, 인크. | A crystalline form of a compound for the treatment or prophylaxis of gout or hyperuricemia |
| CN113164439A (en) * | 2018-12-06 | 2021-07-23 | 安索治疗公司 | Method for treating or preventing gout or hyperuricemia |
| JP2022533958A (en) * | 2019-05-14 | 2022-07-27 | アースローシ セラピューティクス，インク． | Compounds for treating gout or hyperuricemia |
| CA3138419A1 (en) * | 2019-06-17 | 2020-12-24 | Fochon Pharmaceuticals, Ltd. | Heterocyclic derivatives and use thereof |
| TW202214228A (en) * | 2020-06-10 | 2022-04-16 | 美商安索治療公司 | Methods for treating or preventing chronic kidney disease |
| WO2022169974A1 (en) | 2021-02-05 | 2022-08-11 | Nexys Therapeutics, Inc. | Inhibitors of urat1 and pharmaceutical uses thereof |
| TW202330485A (en) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| WO2023125667A1 (en) * | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
| WO2023149549A1 (en) * | 2022-02-03 | 2023-08-10 | 国立大学法人富山大学 | Novel pharmaceutical composition |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1023985A (en) | 1911-05-29 | 1912-04-23 | Louis Emile Beaulieu | Fish-plate bolt. |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| KR0182801B1 (en) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | Method of manufacturing solid dispersion |
| JPH07501073A (en) | 1991-11-22 | 1995-02-02 | プロクター、エンド、ギャンブル、ファーマス−ティカルズ、インコーポレーテッド | risedronate delayed release composition |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE69332291T2 (en) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co., Ltd. | METHOD FOR PRODUCING WAX MATRICES |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
| DE19624292A1 (en) * | 1996-06-18 | 1998-01-02 | Merckle Gmbh | Preparation of optically pure 1'-hydroxy-benz-bromoarone |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| EP1767531A4 (en) * | 2004-06-10 | 2011-01-05 | Torii Pharmaceutical Co Ltd | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof |
| US20080305169A1 (en) * | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| AU2008245662A1 (en) * | 2007-04-26 | 2008-11-06 | Auspex Pharmaceuticals, Inc. | Deuterium labelled ketamine |
| JP5325065B2 (en) * | 2009-09-30 | 2013-10-23 | 株式会社富士薬品 | New phenol derivatives |
| GB2484298A (en) | 2010-10-05 | 2012-04-11 | Plexus Ocean Syst Ltd | Subsea wellhead with adjustable hanger forming an annular seal |
| US10005750B2 (en) | 2010-10-06 | 2018-06-26 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
| US20150031768A1 (en) | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
| US9962362B2 (en) | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| US9725430B2 (en) | 2013-01-16 | 2017-08-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| US20140357683A1 (en) * | 2013-05-31 | 2014-12-04 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treatment and compositions with xanthine oxidase inhibitors |
| WO2015134467A1 (en) * | 2014-03-05 | 2015-09-11 | The Trustees Of Princeton University | Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks |
| RU2017105133A (en) | 2014-07-31 | 2018-08-28 | Мерк Патент Гмбх | INDOLYSINE DERIVATIVES THAT USE FOR NEURODEGENERATIVE DISEASES |
| CN104311516B (en) | 2014-09-16 | 2017-01-11 | 东北制药集团股份有限公司 | Benzbromarone of crystal form B, and its preparation method |
| CN104262305B (en) | 2014-09-16 | 2016-06-08 | 东北制药集团股份有限公司 | A kind of benzbromarone crystal form A and preparation method thereof |
| AU2017298142B2 (en) | 2016-07-18 | 2021-11-11 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| CN113164439A (en) | 2018-12-06 | 2021-07-23 | 安索治疗公司 | Method for treating or preventing gout or hyperuricemia |
| KR20210100677A (en) | 2018-12-06 | 2021-08-17 | 아쓰로시 테라퓨틱스, 인크. | A crystalline form of a compound for the treatment or prophylaxis of gout or hyperuricemia |
-
2017
- 2017-07-12 AU AU2017298142A patent/AU2017298142B2/en active Active
- 2017-07-12 EP EP21185425.2A patent/EP3957629B1/en active Active
- 2017-07-12 JP JP2019502791A patent/JP2019524747A/en active Pending
- 2017-07-12 ES ES17831578T patent/ES2897968T3/en active Active
- 2017-07-12 EP EP17831578.4A patent/EP3484862B1/en active Active
- 2017-07-12 PT PT178315784T patent/PT3484862T/en unknown
- 2017-07-12 ES ES21185425T patent/ES2964344T3/en active Active
- 2017-07-12 KR KR1020197004544A patent/KR102610573B1/en active IP Right Grant
- 2017-07-12 CN CN201780057295.8A patent/CN109790135B/en active Active
- 2017-07-12 EA EA201990333A patent/EA201990333A1/en unknown
- 2017-07-12 SG SG11201900405XA patent/SG11201900405XA/en unknown
- 2017-07-12 CN CN202110361823.7A patent/CN113214198B/en active Active
- 2017-07-12 WO PCT/US2017/041763 patent/WO2018017368A1/en unknown
- 2017-07-12 CN CN202211434030.4A patent/CN116332886A/en active Pending
- 2017-07-12 IL IL264268A patent/IL264268B/en unknown
- 2017-07-12 PL PL17831578T patent/PL3484862T3/en unknown
- 2017-07-12 DK DK17831578.4T patent/DK3484862T3/en active
- 2017-07-12 CA CA3030821A patent/CA3030821A1/en active Pending
-
2018
- 2018-10-04 US US16/151,641 patent/US10239854B2/en active Active
-
2019
- 2019-02-05 US US16/268,367 patent/US10508093B2/en active Active
- 2019-11-14 US US16/684,046 patent/US11236058B2/en active Active
-
2020
- 2020-01-30 JP JP2020014109A patent/JP7418227B2/en active Active
-
2021
- 2021-12-21 US US17/558,370 patent/US20220112171A1/en not_active Abandoned
-
2022
- 2022-08-04 US US17/817,440 patent/US20220396558A1/en not_active Abandoned
- 2022-09-12 JP JP2022144720A patent/JP2022188052A/en active Pending
-
2023
- 2023-03-23 US US18/189,024 patent/US20230227419A1/en not_active Abandoned
- 2023-11-13 US US18/507,999 patent/US20240116888A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201408808WA (en) | Method and system for treatment of biological tissue | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201809474TA (en) | Compositions and methods for bioengineered tissues | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors |